Press coverage about United Therapeutics Corporation (NASDAQ:UTHR) has trended somewhat positive on Thursday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. United Therapeutics Corporation earned a media sentiment score of 0.24 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 47.7236903819662 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- ETFs with exposure to United Therapeutics Corp. : October 27, 2017 (finance.yahoo.com)
- FY2018 EPS Estimates for United Therapeutics Corporation (UTHR) Decreased by Leerink Swann (americanbankingnews.com)
- United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat – Nasdaq (nasdaq.com)
- FY2017 Earnings Forecast for United Therapeutics Corporation (UTHR) Issued By Jefferies Group (americanbankingnews.com)
- United Therapeutics Corporation (UTHR) Given “Hold” Rating at HC Wainwright (americanbankingnews.com)
United Therapeutics Corporation (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, October 25th. The biotechnology company reported $6.27 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.01 by $2.26. United Therapeutics Corporation had a return on equity of 26.24% and a net margin of 30.50%. The business had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same quarter in the prior year, the firm posted $4.23 EPS. The business’s quarterly revenue was up 9.1% compared to the same quarter last year.
A number of research firms recently issued reports on UTHR. Cowen and Company reissued a “hold” rating and issued a $129.00 price objective on shares of United Therapeutics Corporation in a report on Friday, October 27th. HC Wainwright reissued a “hold” rating and issued a $95.00 price objective on shares of United Therapeutics Corporation in a report on Thursday, October 26th. Zacks Investment Research raised shares of United Therapeutics Corporation from a “strong sell” rating to a “hold” rating in a report on Monday, October 9th. TheStreet downgraded shares of United Therapeutics Corporation from a “b-” rating to a “c” rating in a report on Friday, September 29th. Finally, ValuEngine raised shares of United Therapeutics Corporation from a “hold” rating to a “buy” rating in a report on Monday, October 2nd. Five analysts have rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the stock. United Therapeutics Corporation has an average rating of “Hold” and a consensus price target of $132.82.
ILLEGAL ACTIVITY NOTICE: “United Therapeutics Corporation (UTHR) Given Media Impact Score of 0.24” was originally reported by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.com-unik.info/2017/11/02/united-therapeutics-corporation-uthr-given-media-impact-score-of-0-24.html.
In other United Therapeutics Corporation news, CEO Martine A. Rothblatt sold 2,176 shares of the company’s stock in a transaction that occurred on Thursday, August 10th. The stock was sold at an average price of $127.11, for a total value of $276,591.36. Following the sale, the chief executive officer now owns 3,245 shares in the company, valued at approximately $412,471.95. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Martine A. Rothblatt sold 1,274 shares of the company’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total value of $147,873.18. Following the completion of the sale, the chief executive officer now owns 2,343 shares in the company, valued at approximately $271,952.01. The disclosure for this sale can be found here. In the last 90 days, insiders sold 17,120 shares of company stock worth $2,137,660. Insiders own 7.80% of the company’s stock.
About United Therapeutics Corporation
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
What are top analysts saying about United Therapeutics Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for United Therapeutics Corporation and related companies.